Chromosome band 3q26 is the locus of two genes, MDS1/EVI1 and EVI1. The proteins encoded by these genes are nuclear factors each containing two separate DNA-binding zinc finger domains. The proteins are identical, aside from the N-terminal extension of MDS1/EVI1, which is missing in EVI1. However, they have opposite functions as transcription factors. In contrast to MDS1/EVI1, EVI1 is often activated inappropriately by chromosomal rearrangements at 3q26 leading to inappropriate expression of the protein in hematopoietic cells and to myeloid leukemias, which are often characterized by abnormal megakaryopoiesis. We previously showed that the two proteins affect replication and differentiation of progenitor hematopoietic cell lines in opposite ways: whereas EVI1 inhibits the response of 32Dc13 cells to G-CSF and TGF␤1, MDS1/EVI1 has no effect on the G-CSF-induced differentiation of the 32Dc13 cells, and it enhances the growth-inhibitory effect of TGF␤1. In the present study, we analyzed the endogenous expression of the two genes during in vitro hematopoietic differentiation of murine embryonic stem (ES) cells and evaluated the effects of their forced expression on the ability of ES cells to produce differentiated hematopoietic colonies. We found that the expression of the two genes is independently and tightly controlled during differentiation. In addition, the forced expression of EVI1 led to a much higher rate of cell growth before and during differentiation, whereas the expression of MDS1/EVI1 repressed cell growth and strongly reduced the number of differentiated hematopoietic colonies. Finally, our study also found that the forced expression of EVI1 resulted in the differentiation of abnormally high numbers of megakaryocytic colonies, thus providing one of the first experimental models showing a clear correlation between inappropriate expression of EVI1 and abnormalities in megakaryopoiesis.
Introduction
Hematopoiesis is the result of a complex balance between stem cell replication and lineage-specific differentiation which is regulated by many different cytokines and transcription factors promoting the survival, proliferation, or differentiation of the hematopoietic cells. The life-long maintenance and regenerative capacity of the hematopoietic system depends on the correct expression of key regulatory proteins that govern selfrenewal, lineage commitment, and differentiation of hematopoietic stem cells and progenitors. The genes encoding these proteins are frequently affected by chromosomal abnormalities such as translocations, inversions, deletions, or duplications. These abnormalities often contain or are at the site of a tumor suppressor gene or a proto-oncogene, which is either deleted or mutated by the rearrangements. The rearrangeCorrespondence: G Nucifora; Fax: 708 327 3342 Received 21 July 1999; accepted 2 August 1999 ments alter either the biochemical structure or the level of the expression of proteins, often leading to leukemia. [1] [2] [3] A chromosomal site that frequently is rearranged in many chromosomal translocations and inversions identified in myeloid leukemia is the chromosomal band 3q26.
2,4-10 The EVI1 gene is located at 3q26 and targeted by the rearrangements and was first identified in the mouse as the site of retroviral integration associated with myeloid leukemia, and later cloned from human cancer cells. 11, 12 In general, defects of bands 3q26 and 3q21 occur simultaneously by inversion or homologous translocations of chromosome 3, and have been reported in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The characteristic clinical features of these patients are elevated platelet counts, marked hyperplasia with dysplasia of the megakaryocytes, and poor prognosis. [13] [14] [15] [16] [17] EVI1 is an evolutionarily conserved DNA-binding protein that belongs to the Kruppel family of proteins and is characterized by two domains of seven and three repeats of the Cys 2 -His 2 type zinc finger motif. 11, 18 The proximal domain of seven zinc fingers recognizes a DNA consensus site with a central AGATA motif. [19] [20] [21] Recently, we determined that the locus at band 3q26 expresses another gene, MDS1/EVI1, which encodes a longer protein containing the entire EVI1 protein but with an additional, unique N-terminal extension homologous to the evolutionarily conserved PR domain. 22 This domain is similar to the SET domain. 23 We first identified MDS1/EVI1 as the gene located at the breakpoint site of the (3;21)(q26;q22) translocation that is associated with therapy-related MDS/AML and with chronic myelogenous leukemia (CML). This translocation resulted in a fusion gene between the transcription factor AML1 and MDS1/EVI1. 10, 24 Later, we showed that MDS1/EVI1 exists independently of EVI1 and is expressed in several normal human tissues. 22 Although related, the two proteins EVI1 and MDS1/EVI1 are transcription factors that have many opposite properties. Whereas MDS1/EVI1 strongly activates a promoter containing several AGATA repeats, EVI1 cannot activate the same promoter and even represses the activation by MDS1/EVI1. 25 In contrast to EVI1, which blocks the G-CSF-induced differentiation of 32Dc13 cells and abrogates their response to TGF-␤1, the forced expression of MDS1/EVI1 has no effect on the G-CSF-induced differentiation of 32Dc13 cells and renders the cells more sensitive to growth inhibition by TGF-␤1. 26 Finally, in contrast to EVI1, there have been no reports that the overexpression of unrearranged MDS1/EVI1 is associated with myeloid leukemia.
We studied the endogenous expression of the two proteins in murine embryonic stem (ES) cells and the effects of their forced expression on the hematopoietic differentiation of ES cells. We found that the two genes have opposite effects on the growth and differentiation of the ES cells and show that Evi1 and Mds1/Evi1 are differentially regulated during development of EBs. Total RNA from growing EBs was extracted and reverse transcribed as described in Materials and methods. The PCR products were separated by electrophoresis on a 2% agarose gel, and the fragments were identified by ethidium bromide staining and ultraviolet illumination. whereas MDS1/EVI1 impaired the ability of the ES cells to grow in semisolid medium, EVI1 dramatically increased the number and size of the hematopoietic colonies that were produced and strongly favored the differentiation toward the megakaryocytic cells as observed in MDS/AML patients with 3q21q26 rearrangements and overexpresion of EVI1. [13] [14] [15] [16] [17] Thus, the forced expression of EVI1 in differentiating ES cells represents a valuable system for studying EVI1 in myeloid transformation.
Figure 2
Endogenous Mds1/Evi1 is transcribed at a higher level than Evi1 in hematopoietic colonies. Total RNA was extracted from hematopoietic colonies collected from secondary differentiation of naive ES cells (lane 1) and ES cells expressing Evi1 (lane 2) or Mds1/Evi1 (lane 3). Equal amounts of the cDNA reaction were used for amplification of endogenous Mds1/Evi1 (top), Evi1 (middle), and the housekeeping gene Hprt (bottom).
Materials and methods

Plasmids used, ES cell electroporation, and selection
The plasmids used in this study were SR␣-EVI1, SR␣-MDS1/EVI1, and the vector plasmid SR␣MSVtKneo all of which have been described previously. 26 Twenty micrograms of each plasmid DNA, prepared by CsCl gradient, was linearized and electroporated in 1 ml of CCE ES cells (2 × 10 7 ) with a BioRad Gene Pulser (BioRad Laboratories, Hercules, CA, USA). The conditions for electroporation were 290 V and 960 F. After electroporation, the cells were plated on 100 mm plates containing mitomycin C-treated SNL cells and allowed to recover for 48 h. Selection of positive clones was obtained by addition of G418 (150 g/ml). After 10 days, individual clones were isolated, expanded, and used as described later.
ES cell growth and maintenance
Control and transgenic ES cell clones were grown and maintained in an undifferentiated state on a feeder layer of mitomycin C-treated SNL cells 27 in Dulbecco's modified Eagle medium (DMEM), exogenous leukemia inhibitory factor (LIF), 15% fetal bovine serum (FBS), 2 mM L-glutamine, 0.1 mM nonessential amino acids, and 100 M ␤-mercaptoethanol. Before the in vitro differentiation assays, the cells were passaged three times on gelatin-treated plates to eliminate the SNL feeder cells, and 2 days before plating the cells were cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented as described.
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In vitro differentiation of ES cells, colony counting, and staining
For the in vitro differentiation assays, we used the two-step procedure originally described by Keller et al. 28 In the first step (primary differentiation), 1 × 10 3 and 3 × 10 3 ES cells were cultured in 1.5 ml of IMDM with 1% methylcellulose, 15% FBS, and 150 M monothioglycerol and were plated in 35-mm diameter bacterial-grade plates. Cultures were maintained in a humidified incubator with 7.5% CO 2 at 37°C. In these conditions, the ES cells produced compact colonies known as embryoid bodies (EBs), which contain many different cell types, including hematopoietic cells. In the second step of the procedure (secondary differentiation), random pools of 9-day-old EBs were removed from the methylcellulose with sterile pipette tips, and the cells were dissociated by 1 h incubation at 37°C in 0.25% collagenase in phosphatebuffered saline supplemented with 20% FBS. After the incubation, the cells were gently passed through a syringe with a 20-gauge needle to disrupt the EBs and dissociate the cells. The EB-derived cells were counted, and 1 × 10 5 cells were plated in the same conditions described for primary differentiation. The growth factors used include rSCF (25 ng/ml) (Amgen, Thousand Oaks, CA, USA), mIL-3 (20 ng/ml) (R&D Systems, Minneapolis, MN, USA), mGM-CSF (10 ng/ml) (R&D Systems), and hEPO (2 U/ml) (Amgen). Hematopoietic colonies were scored after 8-12 days by colony morphology under phase contrast microscopy, and the validity of the scoring confirmed by Diff-Quik (Dade AG, Dudingen, Switzerland) (similar to Wright-Giemsa) stained cytospins. The size of the EBs was measured by comparison with a size grid. EVI1, but not MDS1/EVI1, induced faster growth of EBs. Control and transgenic ES cell lines were cultured in conditions that forced the differentiation of the ES cells in EBs, as described in Materials and methods. After 3, 6, and 9 days of culture, 
RNA isolation and RT-PCR
Total RNA was isolated from ES cells, EBs, or single colonies using TRIZOL reagent (Sigma, St Louis, MO, USA) according to the manufacturer's instructions. First-strand cDNA necessary for PCR amplification was obtained with the First Strand cDNA Synthesis Kit (MBI Fermentas, Amherst, NY, USA) in a total reaction volume of 20 l, according to the manufacturer's instructions. The primers for amplification of the murine genes Evi1 and Mds1/Evi1 and the murine housekeeping gene Hprt have been described. 28, 29 The PCR reactions were carried out as previously described. 29 Equal volumes of the cDNA reaction mix were used to amplify Evi1 and Mds1/Evi1. The PCR products were separated by electrophoresis on 2% agarose gel, and the fragments were identified by ethidium bromide staining and ultraviolet illumination.
Acetylcholinesterase (AchE) assays
The assays were done with the Megacult-C Kit (Stem Cell Technology, Vancouver, Canada) as suggested by the manufacturer. A total of 1 × 10 5 cells obtained from disaggregated EBs were plated in chamber slides in the presence of the cytokines described and grown at 37°C for 6-8 days. The chamber slides were fixed with ice cold acetone for 5 min and stained as suggested by the manufacturer. The megakaryocytic colonies were identified on the basis of color development. The number of colonies containing megakaryocytes was counted by visual examination with an inverted microscope. 3 
H-thymidine incorporation assays
For 3 H-thymidine incorporation in non-differentiated ES cells, the cells (1 × 10 4 ) were plated in 96-well plates in triplicate, in LIF-containing medium. After 1, 2, and 3 days of incubation, 1 Ci of 3 H-thymidine was added to each well, and the cells were cultured 18 h longer. The cells were collected on a 96-well filter dish, and the incorporated radioactivity was determined by liquid scintillation counting. For 3 H-thymidine incorporation in EBs, ES cells (1 × 10 4 ) were plated in 96-well plates in IMDM containing 15% FBS. After 3, 6, and 9 days of incubation, 1 Ci of 3 H-thymidine was added to each well, and the EBs were incubated for 18 h longer. The cells were collected on a 96-well filter dish, and the incorporated radioactivity was determined by liquid scintillation counting.
Results
Mds1/Evi1 and Evi1 are expressed differentially in ES cells
It was reported recently that the Mds1/Evi1 and the Evi1 genes have a similar pattern of expression in EBs. 29 The EBs are similar to developing embryos and contain cells of many different lineages in addition to hematopoietic cells. Therefore, to determine whether the two genes are expressed specifically in hematopoietic colonies, we induced ES cells to differentiate in EBs and in secondary colonies, and we extracted total RNA for RT-PCR analysis as described in Materials and methods. We observed the development of the EBs for 2 weeks because during that time a wide range of cell types including hematopoietic cells is present in the developing EBs. The RT-PCR technique is widely accepted as a method for expression analysis of specific genes during differentiation of ES cells and has been used by many investigators. 28, [30] [31] [32] [33] [34] Figure 1a shows the results of our RT-PCR analysis. The Mds1/Evi1 gene clearly was expressed at low levels in undifferentiated ES cells ( Figure  1a , day 0). However, as the ES cells were forced to differentiate, the expression of the gene increased to a maximum at days 10-12 ( Figure 1a, top) . In contrast to Mds1/Evi1, the expression of Evi1 in undifferentiated ES cells was undetectable at day 0, but was induced in the EBs after about 6-7 days of differentiation (Figure 1a , middle), with a peak at days 11-12. Figure 1a (bottom) shows the amplification of the Hprt gene, used for normalization of the intensity (shown in Figure 1b) . Our results partially contrast with previously reported results 29 in that our data show that Mds1/Evi1 is expressed clearly in undifferentiated ES cells and that the two genes are regulated differentially.
To determine whether the two genes are expressed specifically in the hematopoietic compartment of the developing EBs, we used RNA extracted from hematopoietic colonies after we plated cells from disrupted EBs in methylcellulosebased medium as described in Materials and methods. In the conditions we used, essentially all the suspension colonies were hematopoietic. The results, shown in Figure 2 , indicate that both genes are also expressed in hematopoietic cells. In contrast to what was observed for the intact EBs, in which cells other than those of hematopoietic lineage were present (Figure 1 ), the expression of Mds1/Evi1 in differentiated hematopoietic colonies seemed to be much stronger than that of Evi1 (Figure 2) . Although it is difficult to make an accurate, quantitative comparison between the two different types of assays, the results suggest that Mds1/Evi1 could be involved in the control of cell growth during differentiation, in agreement with findings described in the next sections and with our previous results for 32Dc13 cells. 26 
Forced expression of transgenic EVI1 and MDS1/EVI1 in ES cells does not alter their endogenous expression
To determine whether forced expression of the transgenes affects the endogenous expression of Mds1/Evi1 and Evi1, which would indicate that there is a feedback mechanism in the regulation of the two genes, we repeated the RT-PCR assays described previously using total RNA extracted from transgenic EBs. CCE ES cells were transfected with empty-vector SR␣MSVtKneo or with vector carrying the human cDNAs of either MDS1/EVI1 or EVI1, and single clones were selected as described in Materials and methods. The expression of the transgenes was confirmed by RT-PCR of DNAse-treated total RNA using as control non reverse-transcribed total RNA. Several independent clones were tested for each transfection. Because the expression of the transgenes varied in the clones tested, we selected three clones of each type with high levels of gene expression (data not shown). The results showed no change in the pattern of expression of the endogenous genes compared with the control cells (Figure 2 ), suggesting that their expression is regulated independently by factors that have not been determined yet.
Forced expression of transgenic EVI1 increases the growth rate of ES cells
We showed previously that the forced expression of EVI1 affects the growth and differentiation of the hematopoietic cell line 32Dc13. 26 To determine whether the expression of the transgenes alters the growth rate of the ES cells as well, we H-thymidine incorporation assays. For these analyses, ES cells were planted in 96-well plates in conditions that force the cells to differentiate into EBs. For these assays it is not advisable to split or re-feed the cells, so our analysis was carried out for 9 days. After that time, the medium was depleted, and we noted cell death, especially in the wells containing the EVI1 cells. The results of the assays are shown in Figure 3 . As the ES cells are forced to differentiate (starting at day 1), they form compact EBs, their replication rate decreases, and as expected, there is a decrease in the rate of 3 H-thymidine incorporation compared with undifferentiated cells (day 0). This effect was observed for the ES cells containing the retroviral vector (Figure 3, open circles) and for the ES cells expressing MDS1/EVI1 (Figure 3, open squares) . However, the forced expression of EVI1 in the EBs had a sharp effect, and no sig- nificant decrease in DNA synthesis was observed during the 9 days of the assay (Figure 3 , gray circles), indicating that inappropriate expression of this gene represses the normal reduction of cell replication that occurs during differentiation. To determine whether the forced expression of EVI1 also affects the growth of undifferentiated ES cells, we repeated the
Forced expression of EVI1 increases the plating efficiency and promotes the growth of megakaryocytic colonies
To determine whether the forced expression of the two transgenes affects the type or size of the hematopoietic colonies that are produced during in vitro differentiation, we used the two-step hematopoietic differentiation assay, as described in Materials and methods. We observed both qualitative and quantitative differences between the colonies expressing the transgenes and the control cells. As expected from the results of the 3 H-thymidine incorporation assays described previously, the ES cells expressing transgenic EVI1 formed much larger and more abundant EBs than the control cells (Table 1) . In contrast, the EBs formed by MDS1/EVI1-ES cells were less abundant and smaller than those of control cells.
The results of the secondary plating assays showed an enhancement of those effects. EVI1-ES cells produced a significantly higher number of very large colonies. However, we consistently detected scarce and small colonies in plates seeded with an equal number of MDS1/EVI1-ES cells, indicating that MDS1/EVI1 reduced the ability of the cells to grow in semisolid medium (Table 1) . These results agree with those of the 3 H-thymidine incorporation assays (Figures 3 and 4) and with the results we reported previously on the effects of the two transgenes in 32Dc13 cells. 26 Taken together, they indicate that EVI1 strongly increases but MDS1/EVI1 inhibits the replicative ability of the ES cells and their potential to grow in semisolid medium.
We also analyzed the type of hematopoietic colonies that developed from the transgenic ES cells. In all cases, most colonies were of mixed lineage, with abundant macrophages and erythrocytes (data not shown). EVI1-ES cells produced more megakaryocytic cells than expected with the mixture of cytokines that we used. In some cases, the megakaryocytic cells represented a significant percentage of the total number of hematopoietic cells ( Figure 5 , top left). MDS1/EVI1-ES colonies, although much smaller, appeared qualitatively normal, with a diverse population of hematopoietic cells as expected ( Figure 5 , top right). To confirm that the differentiated colonies still expressed the transgenes, we performed RT-PCR on RNA extracted from single colonies. The results are shown in Figure 5 (bottom) and confirmed that the expression of the transgenes was maintained in the differentiated clones. The presence and abundance of megakaryocytes for secondary differentiations of all cell lines was confirmed by colorimetric detection of acetylcholinesterase, 35 which is an enzyme specifically synthesized by megakaryocytes. The use of this enzyme as a marker allowed us to count the number of colonies that contained megakaryocytes in plates seeded with control and transgenic ES cells. The results (Table 2) confirmed that the number of EVI1 colonies containing megakaryocytes was much higher than expected. Most of the colonies detected with this marker were small and consisted of about 5-10 cells each, as expected for pure megakaryocytic colonies. In contrast, secondary differentiation of MDS1/EVI1-ES and control ES cells gave similar numbers of colonies containing megakaryocytic cells (Table 2) .
Discussion
Since Evi1 was identified as the integration site of ecotropic retroviruses in murine leukemia, 36, 37 the inappropriate activation of this gene has been associated with the development or progression of many malignant hematopoietic disorders, including myelodysplasia, acute myeloid leukemia, and blast phase chronic myeloid leukemia. [13] [14] [15] [16] [17] Interestingly, all of these human diseases are commonly associated with abnormal megakaryopoiesis, specifically, dysplastic changes along with abnormal proliferation in the megakaryocytes. The in vitro differentiation of ES cells expressing EVI1 recapitulates many of those same changes. Megakaryocytic hyperplasia which produces an abundance of immature megakaryocytes is seen in cells expressing EVI1.
The precise molecular mechanisms mediating those effects are not known. Megakaryocyte-specific promoters are characterized by the presence of GATA and Ets transcription family binding sites, 38, 39 so it is tempting to speculate that overexpression of EVI1 blocks the normal function of GATA family transcription factors. Megakaryocytes lacking the Gata1 transcription factor are hyperproliferative and show a block in terminal differentiation. 40, 41 There is a much earlier block in megakaryopoiesis with essentially no megakaryocytic development in the absence of the GATA coactivator Fog1. 42 Although EVI1 binds to a core AGATA motif and can repress the activation of a GATA1-dependent promoter in vitro, 43 it is not certain that EVI1 is capable of direct competition with GATA transcription factors for naturally occurring binding sites in endogenous megakaryocyte specific genes. Alternatively, EVI1 could produce megakaryocytic hyperplasia blocking the normal growth supression mediated by TGF-␤1, which is a potent supressor of megakaryocyte growth and development. We and others have demonstrated that EVI1 blocks this normal growth suppression mediated by TGF-␤1 signalling in many cell types. 18 These potential mechanisms are, of course, not mutually exclusive.
Our findings support the notion that overexpression of EVI1 is involved in abnormal megakaryopoiesis seen in human hematologic disorders associated with 3q26 chromosomal changes. It will be important to confirm these findings in vivo by using chimeric or transgenic animals.
